Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium-glucose co-transporter 1-mediated glucose absorption in the small intestine

被引:13
|
作者
Chan, Leo K. Y. [1 ]
Wang, Yi [1 ]
Ng, Enders K. W. [2 ]
Leung, Po Sing [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Room 609A, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Fac Med, Shatin, Hong Kong, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 03期
关键词
diabetes; glucose intolerance; NHE3; inhibitor; postprandial hyperglycaemia; HYPOGLYCEMIC AGENT; TRANSPORTER SGLT1; RECEPTOR; ENTEROCYTES; ACTIVATION; KINASE; GROWTH; NHE3;
D O I
10.1111/dom.13151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimTo elucidate the role of Na+/H+ exchanger 3 (NHE3) in sodium-glucose co-transporter 1 (SGLT1)-mediated small intestinal brush border membrane (BBM) glucose absorption and its functional implications in type 2 diabetes mellitus (T2DM). Materials and MethodsHuman jejunal samples were obtained from patients undergoing gastrectomy. C-14-glucose absorption was measured by liquid scintillation counting. NHE3 expression was suppressed by siRNA-mediated knockdown or augmented in Caco2 cells. Glucose and insulin tolerance in db/db and m+/db mice was assessed with oral and intraperitoneal glucose tolerance tests, and an intraperitoneal insulin tolerance test. Insulin resistance and -cell function were assessed using homeostatic model assessment of insulin resistance and -cell function. ResultsNHE3 expression was upregulated in db/db mouse jejunal BBM and high-glucose-treated Caco2 cells. NHE3 blockade impaired SGLT1-mediated glucose absorption in human jejunum, m+/db and db/db mouse jejunums, and Caco2 cells, via serum/glucocorticoid-regulated kinase 1 (SGK1). NHE3 knockdown suppressed SGLT1-mediated glucose uptake and reduced mRNA and protein levels of SGK1 and SGLT1, which were conversely enhanced by NHE3 overexpression. Chronic S3226 treatment diminished postprandial glucose levels and ameliorated glucose intolerance in db/db mice. ConclusionNHE3 is essential in the modulation of small intestinal BBM glucose absorption. Our findings provide a rationale for future possible clinical application of NHE3 for treatment of T2DM through reducing intestinal glucose uptake and counteracting postprandial hyperglycaemia.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 50 条
  • [41] Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
    Kumar, Shubham
    Khatik, Gopal L.
    Mittal, Amit
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2020, 20 (03) : 170 - 182
  • [42] Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
    Kasichayanula, S.
    Chang, M.
    Hasegawa, M.
    Liu, X.
    Yamahira, N.
    LaCreta, F. P.
    Imai, Y.
    Boulton, D. W.
    DIABETES OBESITY & METABOLISM, 2011, 13 (04): : 357 - 365
  • [43] Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Shusuke Yagi
    Ken-ichi Aihara
    Takeshi Kondo
    Kiyoe Kurahashi
    Sumiko Yoshida
    Itsuro Endo
    Daiju Fukuda
    Yutaka Nakaya
    Kin-ichiro Suwaki
    Takashi Takeji
    Toshihiro Wada
    Hotimah Masdan Salim
    Saori Hama
    Tomomi Matsuura
    Takayuki Ise
    Kenya Kusunose
    Koji Yamaguchi
    Takeshi Tobiume
    Hirotsugu Yamada
    Takeshi Soeki
    Tetsuzo Wakatsuki
    Munehide Matsuhisa
    Michio Shimabukuro
    Masashi Akaike
    Masataka Sata
    Advances in Therapy, 2018, 35 : 124 - 134
  • [44] The Sodium-Glucose Co-Transporter SGLT1-Could Light Help Prevent Type II Diabetes?
    Keipert, Christine
    Bick, Inga
    Brosch, Catrin
    Obrdlik, Petr
    Fendler, Klaus
    BIOPHYSICAL JOURNAL, 2010, 98 (03) : 372A - 372A
  • [45] The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    Lajara, Rosemarie
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (17) : 2565 - 2585
  • [46] Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Yagi, Shusuke
    Aihara, Ken-ichi
    Kondo, Takeshi
    Kurahashi, Kiyoe
    Yoshida, Sumiko
    Endo, Itsuro
    Fukuda, Daiju
    Nakaya, Yutaka
    Suwaki, Kin-ichiro
    Takeji, Takashi
    Wada, Toshihiro
    Salim, Hotimah Masdan
    Hama, Saori
    Matsuura, Tomomi
    Ise, Takayuki
    Kusunose, Kenya
    Yamaguchi, Koji
    Tobiume, Takeshi
    Yamada, Hirotsugu
    Soeki, Takeshi
    Wakatsuki, Tetsuzo
    Matsuhisa, Munehide
    Shimabukuro, Michio
    Akaike, Masashi
    Sata, Masataka
    ADVANCES IN THERAPY, 2018, 35 (01) : 124 - 134
  • [47] The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
    Brunton, S. A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (10) : 1071 - 1087
  • [48] Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
    Desai, Mehul
    Yavin, Yshai
    Balis, Dainius
    Sun, Don
    Xie, John
    Canovatchel, William
    Rosenthal, Norm
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 897 - 900
  • [49] Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
    Devineni, Damayanthi
    Curtin, Christopher R.
    Polidori, David
    Gutierrez, Maria J.
    Murphy, Joseph
    Rusch, Sarah
    Rothenberg, Paul L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (06): : 601 - 610
  • [50] Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium-Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
    Reilly, Timothy P.
    Graziano, Michael J.
    Janovitz, Evan B.
    Dorr, Thomas E.
    Fairchild, Craig
    Lee, Francis
    Chen, Jian
    Wong, Tai
    Whaley, Jean M.
    Tirmenstein, Mark
    DIABETES THERAPY, 2014, 5 (01) : 73 - 96